LABTWIN
14.12.2022 12:01:42 CET | Business Wire | Press release
Today, Royal DSM N.V., a global company specializing in health, nutrition, and sustainable living, and LabTwin GmbH, the leading voice and AI-powered digital lab assistant, announce a multi-year license and collaboration agreement. DSM will apply the newly acquired technology in several of their Science & Innovation laboratories globally. Together, we intend to transform how science is performed in research and application labs providing significant value through speeding up innovation cycles at DSM and its partners worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005030/en/
DSM partners with LabTwin to empower scientists with the latest voice and AI solutions. (Graphic: Business Wire)
“We are excited to see that LabTwin is already onboarded on multiple of DSM’s R&D premises globally with more than 100 scientists and technicians, and we are looking forward to supporting them further in their digital transformation journey,” said Magdalena Paluch, CEO of LabTwin.
LabTwin’s digital lab assistant enables hands-free data capture through voice notes or connected lab instruments while working at the bench and provides on-the-go access to safety or operational information. LabTwin also talks scientists through protocols and records any deviations or out of specification results. This data is then automatically structured by LabTwin’s deep learning capabilities and enriched with metadata. The digital assistant will form part of DSM’s wider digitalization strategy, including the full integration with DSM’s Electronic Lab Notebooks.
Willi Gottstein, Scientist and Project Manager at DSM explains “LabTwin has already become the digital assistant of many of our experimentalists, leading to better data and result tracking in the lab, FAIR data processing and more efficient reporting in the office. LabTwin significantly lowers the threshold to record observations leading to higher reproducibility of experiments and easier trouble-shooting.”. Hans Roubos, Director Digital Science and Technologies at DSM continues: “LabTwin offers us a Siri-like experience for the Lab with many options for further advancing our lab operations, from guiding our scientists through laboratory protocols to interacting with labware and storing data and observations in a smart, hands-free way”.
Both DSM and LabTwin shall provide more details on this exciting collaboration in the coming year.
Watch this short product tour video to learn more about LabTwin or follow us on LinkedIn.
LabTwin
LabTwin is creating the next generation of digital lab tools for smart labs, starting with the world's first voice-activated lab assistant. With LabTwin, scientists can collect data, access information, manage experiments and streamline documentation simply by talking. Using voice recognition and machine learning technology, LabTwin’s smart assistant simplifies data capture, structures valuable information, and provides suggestions to scientists in real-time so they can make more informed data-driven decisions. LabTwin is backed by BCG Digital Ventures and Sartorius. Its voice-powered assistant is used in chemical companies and in 7 of the Top20 Pharma around the world.
DSM – Bright Science. Brighter Living. ™
Royal DSM is a global science-based company active in health & nutrition. DSM is organized in three Business Groups: Food & Beverage, Health Nutrition & Care, and Animal Nutrition & Health. Our long-term success in serving these markets require innovations that are customer-focused, value-adding and differentiating and, at the same time, grounded in market insights as well as best-in-class launch execution capabilities. DSM and its associated companies deliver an annual net sales of about €10 billion with approximately 25,000 employees. More information can be found at www.dsm.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005030/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 02:00:00 CEST | Press release
Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 01:58:00 CEST | Press release
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform
Andersen Global styrker sine kompetencer inden for skat og global mobilitet i Tyskland2.7.2026 00:13:00 CEST | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse gennem en samarbejdsaftale med Lohr and Company (L+C), der er en erfaren skatterådgivningsvirksomhed, der leverer praktiske og fleksible løsninger inden for skattecompliance, internationale skatteforhold, global mobilitet og transfer pricing. L+C har hovedkontor i Tyskland og er også til stede i Østrig og rådgiver store multinationale selskaber, familieejede virksomheder, familievirksomheder, fonde og formuende privatpersoner. L+C blev grundlagt i 2001 og har specialiseret sig i global mobilitet, opkøb og fusioner, international skattelovgivning, rapportering mellem lande og transfer pricing, herunder rapportering i henhold til Pillar 2. Derudover bistår L+C sine kunder med trusts og fonde, skattecompliance, løn- og regnskabsadministration samt privatøkonomisk rådgivning. "Samarbejdet med Andersen Global er et vigtigt skridt i udvidelsen af vores internationale kompetencer og styrker den værdi, vi skaber for kunder, der navigerer i stadig mer
Robinhood Chooses Morpho to Power New Earn Product1.7.2026 21:15:00 CEST | Press release
Morpho now powers the infrastructure behind some of the most widely used retail financial platforms in the United States, bringing more options for onchain yield to millions of customers through the apps they already use. Morpho, the open blockchain-based credit network, today announced it will power Robinhood’s new Earn product, enabling Robinhood's millions of eligible users more options to earn yield onchain via a self-custody wallet, directly within the Robinhood app. The product will roll out progressively to Robinhood's US customer base over the coming weeks. The Robinhood Earn product aims to provide risk-adjusted yield on idle balances using USDG, a dollar-pegged stablecoin. Morpho serves as the underlying credit network, Steakhouse Financial curates the vault infrastructure supporting the product, and Robinhood Chain acts as the settlement layer. The product is delivered through a seamless experience in the Robinhood app. Morpho operates as an open network on the blockchain. L
Photonics Innovators Worldwide Invited to Compete for SPIE Prism Awards1.7.2026 20:33:00 CEST | Press release
19th annual award honors exceptional new products transforming light-based technologies SPIE, the international society of optics and photonics, invites the optics and photonics community to apply for this year’s SPIE Prism Awards, which recognize outstanding new products making waves on the market. Honorees will be announced at the highly-anticipated award ceremony on 3 February 2027 at SPIE Photonics West in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701642411/en/ SPIE Prism Awards honor exceptional new products transforming optics and photonics technologies. These awards, dubbed the “Oscars of Photonics,” provide scientists and engineers in the optics and photonics industry the opportunity to showcase their contributions to the field. Finalists and winners receive extensive print, web, and onsite promotion at SPIE Photonics West, which draws more than 22,000 researchers and industry leade
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
